Biopharm company focused on human monoclonal antibodies announced the closing of a EUR 27.5 million Series B round. The round was co-led by OrbiMed and Seventure Partners, with the existing shareholders Forbion Capital, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB also participating.
Read More